Health Insurance, Blood Cancer Care, and Outcomes: A Literature Review

Rákkutatás · Diffuse large B-cell lymphoma

Health insurance status and type materially influence survival and financial toxicity among patients with blood cancer, yet the current evidence is largely retrospective, limited to Medicare and commercial plans, and does not adequately address access to care, clinical trials, or underserved populations.

The Affordable Care Act introduced reforms to improve cancer coverage, yet financial toxicity remains high for blood‑cancer patients, particularly those on costly oral therapies. A systematic review of 154 studies—130 with a focus on insurance—identified gaps and disparities. Survival, most often studied, was improved for insured versus uninsured patients and for those with commercial versus public insurance, though evidence is largely from retrospective registry analyses. Financial burden studies, predominantly of Medicare Part D, demonstrate high out‑of‑pocket costs and adherence issues for high‑cost‑sharing patients; limited data exist for Medicaid, uninsured, and non‑ACA‑compliant plans. Access to care and clinical‑trial participation were inadequately examined, as were outcomes such as quality of care, HR‑QOL, and adverse events. The review highlights a critical need for prospective, well‑controlled studies—including underrepresented populations (adolescents, minorities, rural residents) and diverse insurance products—to inform evidence‑based policy and improve outcomes for patients with blood cancer.

Understanding how insurance shape clinical outcomes and financial burden in blood‑cancer patients is essential for designing policies that reduce disparities, improve access to lifesaving treatments (e.g., transplantation, targeted therapies) and for guiding future research priorities.

Bizonyítékszint: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.

Eredeti forrás

Kapcsolódó jelek